...remained low in FY 2004 as the effects of inspection program changes continued to be felt. Of the 30 issued during the year, 16 addressed stability program deficiencies, while equipment cleaning and QC unit problems appeared on half. Warning letters to foreign firms spiked to six from one the previous year. While Schering-Plough progresses in reinstating its compliance status following a 2002 consent decree, GlaxoSmithKline and Chiron take some enforcement heat. FDA field officials advise that openness during inspections can help their outcome. [The drug and therapeutic biologic cGMP warning letters issued in FY 2004 are listed. The listing is organized according to the type of facility involved and includes the recipient’s name, letter date, plant location, and a description of the problem areas cited.]
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.
The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.
Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.
